Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of extended-release niacin on immune activation in HIV-infected immunological non-responders on effective antiretroviral therapy.
Lebouché B, Yero A, Shi T, Farnos O, Singer J, Kema I, Costiniuk CT, Thomas R, Brouillette MJ, Engler K, Routy JP, Jenabian MA; CTN PT006 Study Group. Lebouché B, et al. Among authors: routy jp. HIV Res Clin Pract. 2020 Dec;21(6):182-190. doi: 10.1080/25787489.2020.1866846. Epub 2021 Jan 6. HIV Res Clin Pract. 2020. PMID: 33403940 Clinical Trial.
Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells.
Tsoukas CM, Turner HM, Hatzakis GE, Blake GP, Goodhew JE, Kilby DL, Kovacs CM, Luetkehoelter JR, Routy JP, Walmsley SL, Bernard NF. Tsoukas CM, et al. Among authors: routy jp. AIDS Res Hum Retroviruses. 2001 Jul 1;17(10):887-900. doi: 10.1089/088922201750290014. AIDS Res Hum Retroviruses. 2001. PMID: 11461675 Clinical Trial.
Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection.
Alter G, Hatzakis G, Tsoukas CM, Pelley K, Rouleau D, LeBlanc R, Baril JG, Dion H, Lefebvre E, Thomas R, Côté P, Lapointe N, Routy JP, Sékaly RP, Conway B, Bernard NF. Alter G, et al. Among authors: routy jp. J Immunol. 2003 Jul 1;171(1):477-88. doi: 10.4049/jimmunol.171.1.477. J Immunol. 2003. PMID: 12817033
High rates of forward transmission events after acute/early HIV-1 infection.
Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R, Rouleau D, Bruneau J, Leblanc R, Legault M, Tremblay C, Charest H, Wainberg MA; Quebec Primary HIV Infection Study Group. Brenner BG, et al. Among authors: routy jp. J Infect Dis. 2007 Apr 1;195(7):951-9. doi: 10.1086/512088. Epub 2007 Feb 16. J Infect Dis. 2007. PMID: 17330784
Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression.
Peretz Y, Ndongala ML, Boulet S, Boulassel MR, Rouleau D, Côté P, Longpré D, Routy JP, Falutz J, Tremblay C, Tsoukas CM, Sékaly RP, Bernard NF. Peretz Y, et al. Among authors: routy jp. Clin Immunol. 2007 Jul;124(1):57-68. doi: 10.1016/j.clim.2007.04.004. Epub 2007 May 22. Clin Immunol. 2007. PMID: 17521962
460 results